v3.24.1.1.u2
Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Research and development expenses:    
Expenses incurred $ 375 $ 605
Less- government participation (180)
Research and development expenses, net 195 605
Marketing expenses 168 172
General and administrative expenses 295 575
Total operating loss 658 1,352
Financial income, net (1) (2)
Loss for the period $ 657 $ 1,350
Basic loss per common stock $ (0.01) $ (0.02)
Dilutive loss per common stock $ (0.01) $ (0.02)
Weighted-average shares basic 69,931,056 68,829,424
Weighted-average shares diluted 69,931,056 68,829,424

Source